ArticleCVIR endovascular2026
Clinical efficacy and safety of the Jetstream Atherectomy System in Chinese Patients with femoropopliteal artery occlusive disease.
Article in CVIR endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis prospective, multicenter, single-arm clinical trial evaluated the safety and efficacy of the Jetstream Atherectomy System in 72 Chinese patients with calcified femoropopliteal artery occlusive disease (FPOAD). MATERIALS AND
methodsThe study protocol was approved by the institutional review boards of all participating centers, and all participants provided written informed consent. The primary endpoints were 30-day major adverse events (MAE) and changes in angiographic stenosis. Secondary endpoints included vessel patency, clinical improvement, and adverse events during follow-up.
resultsThe study cohort had a mean age of 67.5 ± 9.0 years, with a high prevalence of hypertension (79.2%) and diabetes (37.5%). Severe calcification (PACSS, Peripheral Arterial Calcium Scoring System, grade 3-4) was present in 43.1% of lesions. Technical success (≤ 30% residual stenosis) was achieved in 91.7% of cases. The 30-day major adverse events (MAE) rate was 1.4%, with one target lesion revascularization (TLR), and no deaths or amputations were recorded. Mean stenosis was reduced from 87.8 to 48.5%, with a mean lumen gain of 40.2%. At 12 months, primary patency was 68.4%; secondary patency was 89.7%. Clinical improvement was evidenced by an increase in the mean ankle-brachial index (ABI) from 0.52 ± 0.15 to 0.76 ± 0.18, and 91.7% (66/72) of patients showed an improvement of at least one Rutherford class after 1 year.
conclusionsThis study confirms the Jetstream system's clinical value in Chinese FPOAD patients. Its combination of mechanical cutting and aspiration makes it particularly suitable for Asian-specific calcified lesions, achieving favorable clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.